Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
SALIX PHARMACEUTICALS LTD (SLXP)
|
Add to portfolio |
|
|
|
| Price: |
$44.89
| | Metrics |
| OS: |
64.2
|
M
| |
-794
|
% ROE
|
| Market cap: |
$2.88
|
B
| |
-5
|
% ROIC
|
|
Net debt:
|
$1.78
|
B
| |
|
|
|
EV:
|
$4.66
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($102)
|
M
| |
|
|
|
EBIT
|
($325)
|
M
| |
|
|
| EPS |
($6.50)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 |
| Revenues | 1,133.5 | 913.8 | 735.4 | 540.5 | 337.0 | 232.9 | 178.8 | 235.8 |
| Revenue growth | 24.0% | 24.2% | 36.1% | 60.4% | 44.7% | 30.3% | -24.2% | 13.1% |
| Cost of goods sold | 553.9 | 222.5 | 169.9 | 95.4 | 68.7 | 63.5 | 36.7 | 55.0 |
| Gross profit | 579.6 | 736.0 | 610.8 | 445.1 | 268.3 | 169.4 | 142.1 | 180.8 |
| Gross margin | 51.1% | 80.5% | 83.1% | 82.4% | 79.6% | 72.7% | 79.5% | 76.7% |
| Selling, general and administrative | 660.1 | 342.4 | 296.5 | 219.5 | 156.1 | 120.0 | 95.1 | 86.5 |
| Research and development | 170.3 | 112.8 | 85.0 | 71.9 | 73.3 | 89.5 | 83.7 | 73.8 |
| EBITA | -111.6 | 297.1 | 259.0 | 126.8 | 38.8 | -28.6 | -46.7 | 11.9 |
| EBITA margin | -9.8% | 32.5% | 35.2% | 23.5% | 11.5% | -12.3% | -26.1% | 5.0% |
| Amortization of intangibles | 216.1 | 44.7 | 45.4 | 10.9 | 10.4 | 11.5 | | |
| EBIT | -327.8 | 252.3 | 213.7 | 115.9 | 28.5 | -40.1 | -46.7 | 11.9 |
| EBIT margin | -28.9% | 27.6% | 29.1% | 21.4% | 8.5% | -17.2% | -26.1% | 5.0% |
| Pre-tax income | -663.6 | 192.3 | 111.8 | 86.1 | -24.2 | -45.6 | -47.7 | 15.2 |
| Income taxes | -248.7 | 61.5 | 47.6 | -1.3 | 2.9 | -2.0 | -0.1 | 7.0 |
| Tax rate | 37.5% | 32.0% | 42.5% | | | 4.4% | 0.2% | 45.8% |
| Net income | -414.9 | 130.8 | 64.2 | 87.4 | -27.1 | -43.6 | -47.6 | 8.2 |
| Net margin | -36.6% | 14.3% | 8.7% | 16.2% | -8.0% | -18.7% | -26.6% | 3.5% |
| |
| Diluted EPS | ($6.53) | $1.99 | $1.01 | $1.33 | ($0.47) | ($0.88) | ($0.99) | $0.17 |
| Shares outstanding (diluted) | 63.5 | 65.7 | 63.7 | 65.5 | 57.3 | 49.4 | 47.9 | 48.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|